ApconiX at SOT!

We had a fabulous first SOT with the new company.  All our colleagues old and new were so interested to hear about we offer and the successes we have enjoyed in the first few months.  What a great ApconiX team effort creating the booth, the literature and the Pandora’s box chocolate giveaway!    We had a lot of interest in our posters ‘Development and use of in vitro alternatives by the Pharmaceutical Industry‘ and ‘Target organ profiles in toxicity studies supporting human dosing: does severity progress with longer duration of exposure?‘    I also had fun in the SOT debate arguing against the motion ‘NonClinical Toxicology Testing Predicts Clinical Outcome‘! It was declared a draw; lets see what happens when I argue for the motion at EUROTOX September 2016.

By |2018-05-30T16:43:12+00:00March 22nd, 2016|Events|Comments Off on ApconiX at SOT!

About the Author:

Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath Director and Cofounder, ApconiX, UK and Chair and Director of Drug Discovery, University of Birmingham, UK Ruth is chair of drug discovery at Birmingham University, UK and Cofounder of ApconiX, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Previously, Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of Toxicology for Aventis. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development. With >140 publications in peer reviewed journals, she is focused on reducing attrition attributable to safety and toxicity. A former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and president elect of the Academy of Toxicological Sciences, Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology.